MAPT and Alzheimer disease: Baseline CSF sTREM2, progranulin, p-tau, t-tau concentration, Aβ42/Aβ40 ratio, and adjusted brain volume of CN group with amyloid-negative, CN, MCI, and AD groups with amyloid-positive.